Bio­gen ex­tends its set­back streak as Japan­ese reg­u­la­tors push back against their con­tro­ver­sial Alzheimer's drug

An­oth­er bad week for Bio­gen and its Tokyo-based part­ners at Ei­sai was ex­tend­ed on Wednes­day with news that a pan­el re­view of their con­tro­ver­sial Alzheimer’s drug ad­u­canum­ab earned a push­back from the health min­istry in Japan.

Ac­cord­ing to overnight news re­ports, their pan­el con­clud­ed that in­con­sis­tent Phase III da­ta and lack of clin­i­cal sig­nif­i­cance in re­duc­ing amy­loid plaque in pa­tients made it dif­fi­cult to de­ter­mine if the ther­a­py worked, but of­fered to re­view it again once the 2 part­ners lined up more da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER